JPRN-UMIN000011472已完成2 期
Phase II study of erlotinib monotherapy for elderly patients with untreated advanced non-small cell lung cancer, 75 years-old or older, and positive EGFR mutation status (OSAKA-LCSG1303) - OSAKA-LCSG1303
OSAKA-LCSG0 个研究点目标入组 31 人开始时间: 2013年8月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Problematic infection that requires anti-biotic, anti-fungal agent or anti-viral agent (2)Current or previous history of pulmonary fibrosis, interstitial pneumonitis or drug-induced pneumonia, revealed by chest CT or with clinical symptoms (3) A history of severe hypersensitivity against erlotinib (4) Difficulty in oral administration of erlotinib, functional / organic impairment or inflammatory bowel disease that disturbs absorption of erlotinib (5) Another active advanced malignancy that requires any concurrent treatment with treatment for lung cancer (6) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy (7) Psychologically ineligible (8) Decision of ineligibility by a physician
研究者
相似试验
已完成
2 期
A phase II study of Erlotinib for elderly patients previously treated non-small cell lung cancer without epidermal growth factor receptor mutationon-small cell lung cancerJPRN-UMIN000004561Fukushima Medical University, cancer center44
已完成
2 期
Multicenter PhaseII trial of erlotinib for elderly patients with advanced or recurrent non-small cell lung cancer.elderly patients with refractory or recurrent non-small cell lung cancer non-small cell lung cancerJPRN-UMIN000003271ung Oncology Group in Kyushu, Japan (LOGIK)44
已完成
2 期
PhaseII trial of erlotinib for elderly patients with advanced or recurrent non-small cell lung cancerJPRN-UMIN000001873Keio University School of Medicine Division of Pulmonary Medicine40
已完成
2 期
Phase II study of erlotinib monotherapy for patients with advanced stage of non-small cell lung cancer, undetectable epidermal growth factor receptor (EGFR) mutations by PNA LNA PCR clamp method, but positive immuno-staining with anti-EGFR mutation-specific antibodies.on-small cell lung cancerJPRN-UMIN000014299Dept. of Respiratory Medicine, Osaka Police Hospital7
已完成
2 期
Phase II study of erlotinib monotherapy for patients with untreated advanced non-small cell lung cancer, poor performance status and positive EGFR mutation status (OSAKA-LCSG1304)JPRN-UMIN000011473OSAKA-LCSG23